Voyager Therapeutics (VYGR) Enterprise Value (2014 - 2026)

Voyager Therapeutics has disclosed Enterprise Value across 13 years of filings, most recently posting -$141.5 million for Q1 2026.

• Enterprise Value for Q1 2026 came in at -$141.5 million, up 40.06% year-over-year; the trailing twelve-month figure through Mar 2026 was -$141.5 million (up 40.06% YoY), and the FY2025 annual result was -$196.4 million, up 26.34% from the prior year.
• Enterprise Value came in at -$141.5 million for Q1 2026 at Voyager Therapeutics, up from -$196.4 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$118.8 million in Q4 2022 to a low of -$399.6 million in Q1 2024.
• The 5-year median for Enterprise Value is -$230.9 million (2023), against an average of -$233.9 million.
• Across the five-year window, Enterprise Value slumped 94.26% in 2023 and surged 41.89% in 2025, its largest moves.
• Voyager Therapeutics' Enterprise Value stood at -$118.8 million in 2022, then plunged by 94.26% to -$230.9 million in 2023, then dropped by 15.51% to -$266.7 million in 2024, then gained by 26.34% to -$196.4 million in 2025, then advanced by 27.98% to -$141.5 million in 2026.
• The last three Enterprise Value figures came in at -$141.5 million (Q1 2026), -$196.4 million (Q4 2025), and -$208.9 million (Q3 2025), per Business Quant data.